INV-6452

N/A

Report date: 2026/03/27 20:01:50
NME

Base Information

Drug NameINV-6452
Drug Alias NameINV-6452
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 2 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 2Cyclin-dependent kinase 4
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen Ionova Life Sciences Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Juyuan Biotechnology Co LtdGuangdong Innovative Medicine Translational Medicine Research Institute Co LtdFoshan Innova Life Sciences Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A